Glass Lewis Backs Pacira Management in Proxy Fight, Citing 'Actionable Plan'
Summary
Glass Lewis, a prominent proxy advisory firm, has endorsed Pacira BioSciences' strategic plan, concluding it is actionable and designed to deliver substantial stockholder value by 2030. This positive recommendation comes amidst an ongoing and contentious proxy battle with activist investor DOMA Perpetual Capital Management, who has nominated directors and sought to remove the CEO. Such an endorsement from a major proxy advisor can significantly sway institutional shareholder votes, bolstering current management's position in the fight.
At the time of this announcement, PCRX was trading at $23.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $931.5M. The 52-week trading range was $18.80 to $27.64. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.